Hysteretic Behavior of Proprotein Convertase 1/3 (PC1/3)

Total Page:16

File Type:pdf, Size:1020Kb

Hysteretic Behavior of Proprotein Convertase 1/3 (PC1/3) Hysteretic Behavior of Proprotein Convertase 1/3 (PC1/3) Marcelo Y. Icimoto1, Nilana M. Barros2, Juliana C. Ferreira1, Marcelo F. Marcondes1, Douglas Andrade1, Mauricio F. Machado1, Maria A. Juliano1, Wagner A. Ju´ dice3, Luiz Juliano1, Vitor Oliveira1* 1 Departamento de Biofı´sica, Universidade Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil, 2 Cieˆncias Exatas e da Terra, Universidade Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil, 3 Centro Interdisciplinar de Investigac¸a˜o Bioquı´mica, Universidade de Mogi das Cruzes, Sa˜o Paulo, Brazil Abstract The proprotein convertases (PCs) are calcium-dependent proteases responsible for processing precursor proteins into their active forms in eukariotes. The PC1/3 is a pivotal enzyme of this family that participates in the proteolytic maturation of prohormones and neuropeptides inside the regulated secretory pathway. In this paper we demonstrate that mouse proprotein convertase 1/3 (mPC1/3) has a lag phase of activation by substrates that can be interpreted as a hysteretic behavior of the enzyme for their hydrolysis. This is an unprecedented observation in peptidases, but is frequent in regulatory enzymes with physiological relevance. The lag phase of mPC1/3 is dependent on substrate, calcium concentration and pH. This hysteretic behavior may have implications in the physiological processes in which PC1/3 participates and could be considered an additional control step in the peptide hormone maturation processes as for instance in the transformation of proinsulin to insulin. Citation: Icimoto MY, Barros NM, Ferreira JC, Marcondes MF, Andrade D, et al. (2011) Hysteretic Behavior of Proprotein Convertase 1/3 (PC1/3). PLoS ONE 6(9): e24545. doi:10.1371/journal.pone.0024545 Editor: Vladimir N. Uversky, University of South Florida College of Medicine, United States of America Received June 17, 2011; Accepted August 12, 2011; Published September 15, 2011 Copyright: ß 2011 Icimoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This work was supported by Fundac¸a˜o de Amparo Pesquisa do Estado de Sa˜o Paulo (FAPESP), Coordenac¸a˜o de Aperfeic¸oamento de Pessoal de Nı´vel Superior (CAPES), Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq) – Instituto Nacional de Fluidos complexos (INCT-Fx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * E-mail: [email protected] Introduction environment [11] and along the secretory pathway PC1/3 finds an environment that pH decreases from 6.7 to 5.5 [12]. It also known Mammalian subtilases of yeast-kexin type are called proprotein that in the secretory granules calcium concentration can raise up convertases (PCs) or subtilisin-like proprotein convertases (SPCs) to milimolar concentrations [13], [14]; and the peptidase activities [1]. PCs are calcium-dependent proteases responsible for the of 87 and 66-kDa forms of PC1/3 are increased in calcium ion processing/maturation of precursors proenzymes, neural and concentrations range 1 to 20 mM [11]. PC1/3 was reported to hormonal peptides, serum proteins, growth factors and surface present complex enzymatic kinetics for the hydrolysis of substrates glycoproteins of pathogenic bacteria and viruses [2], [3]. This [15], and a lag phase (pre-steady-state) in the initial 8 to family of peptidases is composed by PC1/3, PC2, furin, PC4, 10 minutes followed by a linear phase with a constant velocity PACE4, PC5/6, PC7/8, SKI-1 and NARC-I [4]. Furin, PACE4, of hydrolysis (steady-state) was reported [11]. PC5-B, and PC7 are preferentially expressed in the constitutive The aim of the present paper was to explore the unusual lag secretory pathway, whereas PC1/3, PC2, and PC5-A are active in phase observed in the time course of activity of mPC1/3 as the secretory granules of the regulated secretory pathway of showed in Figure 1 for hydrolysis of the commercially available endocrine and neuroendocrine tissues [5]. fluorogenic substrate pERTKR-AMC. In addition to this peptide All PCs have in tandem disposition the following structures: N- we also examined the hydrolysis of fluorescence resonance energy terminal signal peptide followed by profragment region, conserved subtilisin-like catalytic domain, conserved P-domain and divergent transfer (FRET) peptides based on the PC1/3 natural consensus C-terminal tail [4]. PC1/3 initiates the formation of the active cleavage sites (indicated by the arrows): Abz-YTPKSRRQEVED- forms of neuropeptides by cleaving the precursor proteins after Q-EDDnp, (proinsulin: NP_032412), Abz-SPREGKRQSYSM- pairs of basic residues [6], the same general and conserved motif Q-EDDnp (POMC: EDL01384) and Abz-SKRSRRQSVSV-Q- recognized by the majority of PCs [2]. PC1/3 is synthesized as a EDDnp (Japanese encephalitis virus polyprotein: AAT00231) 753-amino acid zymogen [7], [8] and undergoes autocatalytic [Abz, ortho-aminobenzoic acid; Q-EDDnp, glutamyl-N-(2,4-dini- intramolecular processing of its N-terminal profragment in the ER trophenyl) ethylenediamine]. The last FRET substrate was [9], [10]. The generated 87-kDa protein is targeted to the selected from a series of sixty substrates previously designed for regulated secretory pathway where it is further shortened by furin studies [16]. The influence of calcium ion concentration and removal of 135 amino acids of its C-terminal tail, resulting in the the pH on mPC1/3 activity lag phase were also examined. Finally, 66-kDa form [8]. This C-terminal cleavage occurs at the dibasic we verify if the mPC1/3 possesses the same uncomom kinetic Arg-Arg617–618 site, possibly by an autocatalytic event and this tail behaviour with the larger substrate human salivary histatin-3, a has been proposed to play a role in sorting of PC1/3 to the histidine-rich peptide with 32 amino that was reported to be a regulated secretory pathway [7]. The reported pH assays showed substrate for PC1/3 [17]. Histatin 3 was synthesized, and the that both 87 and 66-kDa forms have higher activity in acidic exclusive cleavage at the carboxyl side of R25 (DSHAKRHH- PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24545 Hysteretic Behavior of PC1/3 were produced by the Fmoc procedure in an automated bench top simultaneous multiple solid-phase peptide synthesizer (PSSM 8 system from Shimadzu, Tokyo, Japan). The final deprotected peptides were purified by HPLC (Shimadzu, Tokyo, Japan) in a semi-preparative column. The molecular mass and purity of the synthesized peptides were checked by Maldi-TOF and/or peptide sequencing with a PPSQ-23 protein sequencer (Shimadzu, Tokyo, Japan). The concentration of the Abz peptide solutions was determined by measuring the absorption of the 2,4-dinitrophenyl group at 365 nm (l = 17,300 M21 cm21). The pERTKR-MCA (pE = pyroglutamic acid) was purchased from Peptanova (Sand- hausen, Germany). Determination of hysteretic parameters mPC1/3 activities were monitored spectrofluorometrically in a Hitachi F-2500 spectrofluorometer using the FRET peptides as substrates, with wavelengths of excitation at 320 nm and emission at 420 nm for Abz, and excitation at 380 and emission at 460 nm Figure 1. Time course of pERTKR-MCA (pE = pyrogluthamyl and for MCA peptide. A standard cuvette (1 cm pathlength) MCA = 7-amino-4-methyl coumarin) hydrolysis by 66-kDa containing 0.5 mL of substrate solution was placed in a mPC1/3. The MCA release increases with time and the exponential thermostatically-controlled cell compartment for 5 min before transient phase (lag phase) precedes the linear steady-state phase. the addition of enzyme. The kinetic parameters of peptide Hydrolysis conditions: mPC1/3 = 20 nM, Buffer = 20 mM BisTris, 20 mM hydrolysis were determined in 20 mM BisTris pH 6.0 at 37uC, CaCl2, pH 6.0 at 37uC. A.U.F. = Arbitrary Units of Fluorescence. doi:10.1371/journal.pone.0024545.g001 any other condition is indicated in the text. The pH values were adjusted at 25uC and checked before assays at 37uC using a model GYKRKFHEKHHSHRGYR25QSNYLYDN) by mPC1/3 was 710A Orion pH meter with an automatic temperature compen- analyzed. sation (ATC) glass probe. The reactions were monitored continuously based on the Materials and Methods fluorescence of the released product. The time course of product generated by mPC1/3 cleavage was fitted to the exponential Enzyme preparation function Equation 1 using the software Grafit version 5.0 Mouse PC1 was produced by overexpression in CHO cells using (Erithacus Software, Horley, Surrey, U.K.), and the hysteretic the dihydrofolate reductase-coupled amplification method. The parameters (k, t,vss and vi) were obtained. expression and purification procedure were earlier reported [18], ÀÁ but several modifications were made. We used motionless T-75 {t:k ½Product ~vsst{ðÞvss{vi 1{e k ð1Þ bottles (Corning Life Sciences, Lowell, MA, USA) instead of roller bottles in order to reduce cell lysis during expression and thus the where vi is the initial velocity, vss is the steady-state velocity and k is contaminants. Each expression gives a different proportion of 87, 74 the apparent rate constant for the transition between vi and vss. and 66-kDa mPC1/3 forms, and many expressions were conducted The secondary constant induction time t (k21) can also be until the pool obtained had the form of 66-kDa as the major obtained. This parameter can be understood as the time required component of the medium, according to SDS-PAGE analysis. The to reach the steady state. The rate of increase in fluorescence was pooled conditioned medium was filtered through a 0.25 mmfilter converted into moles of substrate hydrolyzed per second based on (Millex), diluted 1:3 in buffer A (20 mM Bis-Tris, 2 mM CaCl2, the fluorescence curves of standard peptide solutions after total 0.02% NaN3, and 0.4 mM octylglucoside, pH 7.0) and then enzymatic hydrolysis.
Recommended publications
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Intracellular Peptides: from Discovery to Function
    e u p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 143–151 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.elsevier.com/locate/euprot Intracellular peptides: From discovery to function a,∗ b a,c d,∗∗ Emer S. Ferro , Vanessa Rioli , Leandro M. Castro , Lloyd D. Fricker a Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, SP, Brazil b Special Laboratory of Applied Toxicology-CeTICS, Butantan Institute, São Paulo, SP, Brazil c Department of Biophysics, Federal University of São Paulo, São Paulo, SP, Brazil d Department of Molecular Pharmacology and Neuroscience, Albert Einstein College of Medicine, Bronx, NY, USA a r t i c l e i n f o a b s t r a c t Article history: Peptidomics techniques have identified hundreds of peptides that are derived from proteins Received 8 October 2013 present mainly in the cytosol, mitochondria, and/or nucleus; these are termed intracellular Received in revised form peptides to distinguish them from secretory pathway peptides that function primarily out- 29 November 2013 side of the cell. The proteasome and thimet oligopeptidase participate in the production and Accepted 14 February 2014 metabolism of intracellular peptides. Many of the intracellular peptides are common among mouse tissues and human cell lines analyzed and likely to perform a variety of functions Keywords: within cells. Demonstrated functions include the modulation of signal transduction, mito- Peptides chondrial stress, and development; additional functions will likely be found for intracellular Cell signaling peptides.
    [Show full text]
  • A Case of Prohormone Convertase Deficiency Diagnosed with Type 2 Diabetes
    Turkish CASE REPORT Archives of DOI: 10.14744/TurkPediatriArs.2020.36459 Pediatrics A case of prohormone convertase deficiency diagnosed with type 2 diabetes Gülin Karacan Küçükali1 , Şenay Savaş Erdeve1 , Semra Çetinkaya1 , Melikşah Keskin1 , Ayşe Derya Buluş2 , Zehra Aycan1 1Department of Pediatric Endocrinology, University of Health Science, Dr. Sami Ulus Obstetrics and Gynecology, Children’s Health and Disease Training and Research Hospital, Ankara, Turkey 2Department of Pediatric Endocrinology, University of Health Science, Keçiören Training and Research Hospital, Ankara, Turkey What is already known ABSTRACT on this topic? Prohormone convertase 1/3, encoded by the proprotein convertase subtilisin/kexin type 1 gene, • Prohormone convertase defi- is essential for processing prohormones; therefore, its deficiency is characterized by a defi- ciency is characterized by a de- ciency of variable levels in all hormone systems. Although a case of postprandial hypoglycemia ficiency of variable levels in all has been previously reported in the literature, prohormone convertase insufficiency with type hormone systems. 2 diabetes mellitus has not yet been reported. Our case, a 14-year-old girl, was referred due to • Postprandial hypoglycemia is a excess weight gain. She was diagnosed as having type 2 diabetes mellitus based on laboratory disorder of glucose metabolism test results. Prohormone convertase deficiency was considered due to the history of resistant reported in this disease. diarrhea during the infancy period and her rapid weight gain. Proinsulin level was measured as >700 pmol/L(3.60-22) during diagnosis. In genetic analysis, a c.685G> T(p.V229F) homozygous mutation in the PCSK1 gene was detected and this has not been reported in relation to this dis- order.
    [Show full text]
  • Electronic Supplementary Material (ESI) for Analyst. This Journal Is © the Royal Society of Chemistry 2020
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 Table S1.
    [Show full text]
  • 1.2.Obesity-Pathophysiology.Pdf
    What Is the Disease of Obesity? Obesity Pathophysiology Obesity Has Multiple Pathophysiologic Origins Epigenetic Environmental Genetic Obesity Sociocultural Physiologic Behavioral Bray GA, et al. Lancet. 2016;387:1947-1956. 2 Obesity Pathophysiology Genetic and Epigenetic Origins 3 Genetic Determinants of Obesity Supported by Genome-Wide Association Studies Gene Tissue expressed Gene product / role in energy balance MC4R Adipocyte, hypothalamus, liver Melanocortin 4 receptor / Appetite stimulation; monogenic cause of obesity ADRB3 Visceral adipose tissue β3-Adrenergic receptor / Regulates lipolysis PCSK1 Neuroendocrine cells (brain, Proprotein convertase 1 / Conversion of hormones (including insulin) pituitary and adrenal glands) into metabolically active forms BDNF Hypothalamus Brain-derived neurotrophic factor / Appetite stimulation; regulated by MC4R signaling and nutritional state LCT Intestinal epithelial cells Lactase / Digestion of lactose MTNR1B Nearly ubiquitous Melantonin receptor 1 B / Regulation of circadian rhythms TLR4 Adipocyte, macrophage Toll-like receptor 4 / Lipolysis, inflammatory reactions ENPP1 Nearly ubiquitous Ecotnucleotide pyrophosphatase/phosphodiesterase 1 / Inhibits tyrosine kinase activity of the insulin receptor, downregulating insulin signaling and decreasing insulin sensitivity FGFR1 Adipose, hypothalamus Fibroblast growth factor receptor 1 / Hypothalamic regulation of food intake and physical activity LEP, LEPR Adipocyte Leptin, leptin receptor / Appetite inhibition den Hoed M, Loos RJF. In: Bray GA, Bouchard
    [Show full text]
  • Discovery of an Allosteric Site on Furin, Contributing to Potent Inhibition: a Promising Therapeutic for the Anemia of Chronic Inflammation
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2014-07-01 Discovery of an Allosteric Site on Furin, contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation Andrew Jacob Gross Brigham Young University Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Chemistry Commons BYU ScholarsArchive Citation Gross, Andrew Jacob, "Discovery of an Allosteric Site on Furin, contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation" (2014). Theses and Dissertations. 6537. https://scholarsarchive.byu.edu/etd/6537 This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected]. Discovery of an Allosteric Site on Furin, Contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation Andrew J. Gross A dissertation submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Richard K. Watt, Chair Dixon J. Woodbury Roger G. Harrison Chad R. Hancock John T. Prince Department of Chemistry and Biochemistry Brigham Young University July 2014 Copyright © 2014 Andrew J. Gross All Rights Reserved ABSTRACT Discovery of an Allosteric site on Furin, Contributing to potent Inhibition: A promising Therapeutic for the Anemia of Chronic Inflammation Andrew J. Gross Department of Chemistry and Biochemistry, BYU Doctor of Philosophy Anemia of chronic inflammation (ACI) is a condition that develops in a setting of chronic immune activation. ACI is characterized and triggered by inflammatory cytokines and the disruption of iron homeostasis.
    [Show full text]
  • PCSK9 Biology and Its Role in Atherothrombosis
    International Journal of Molecular Sciences Review PCSK9 Biology and Its Role in Atherothrombosis Cristina Barale, Elena Melchionda, Alessandro Morotti and Isabella Russo * Department of Clinical and Biological Sciences, Turin University, I-10043 Orbassano, TO, Italy; [email protected] (C.B.); [email protected] (E.M.); [email protected] (A.M.) * Correspondence: [email protected]; Tel./Fax: +39-011-9026622 Abstract: It is now about 20 years since the first case of a gain-of-function mutation involving the as- yet-unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 (PCSK9), was described. It was soon clear that this protein would have been of huge scientific and clinical value as a therapeutic strategy for dyslipidemia and atherosclerosis-associated cardiovascular disease (CVD) management. Indeed, PCSK9 is a serine protease belonging to the proprotein convertase family, mainly produced by the liver, and essential for metabolism of LDL particles by inhibiting LDL receptor (LDLR) recirculation to the cell surface with the consequent upregulation of LDLR- dependent LDL-C levels. Beyond its effects on LDL metabolism, several studies revealed the existence of additional roles of PCSK9 in different stages of atherosclerosis, also for its ability to target other members of the LDLR family. PCSK9 from plasma and vascular cells can contribute to the development of atherosclerotic plaque and thrombosis by promoting platelet activation, leukocyte recruitment and clot formation, also through mechanisms not related to systemic lipid changes. These results further supported the value for the potential cardiovascular benefits of therapies based on PCSK9 inhibition. Actually, the passive immunization with anti-PCSK9 antibodies, evolocumab and alirocumab, is shown to be effective in dramatically reducing the LDL-C levels and attenuating CVD.
    [Show full text]
  • PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression
    Research Article PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression Daniel E. Bassi,1,3 Ricardo Lopez De Cicco,1 Jonathan Cenna,1 Samuel Litwin,2 Edna Cukierman,2 and Andres J.P. Klein-Szanto1,3 Departments of 1Pathology and 2Biomathematics and Biostatistics, and 3Tumor Cell Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania Abstract and studying the in vivo effects after overexpressing genes, such as h Collagen type IV degradation results in disruption and transforming growth factor- (3), epidermal growth factor receptor breakdown of the normal basement membrane architecture, (4), and insulin-like growth factor (5). a key process in the initiation of tumor microinvasion into the Proprotein convertases constitute a family of serine proteases that activate their cognate substrates by limited proteolysis at consensus connective tissue. PACE4, a proprotein convertase, activates # membrane type matrix metalloproteinases (MT-MMPs) that in sequence RXR/KR (6). Many of these, such as insulin-like growth turn process collagenase type IV. Because PACE4 is overex- factor-I (7) and its receptor (8), membrane-type matrix metal- pressed in skin carcinomas and in vitro overexpression of loproteinase (MT-MMP; refs. 9, 10), and integrins (11–14) have direct PACE4 resulted in enhanced invasiveness, we investigated roles in tumor progression and metastasis. Although proprotein whetherornotin vivo PACE4 expression leads to the convertases recognize and cleave a specific sequence, variations in the amino acid sequences that surround this motif, as well as acquisition of invasiveness and increased tumorigenesis. Two transgenic mouse lines were designed by targeting PACE4 to preferences in K or R preceding the COOH-terminal R, account for the epidermal basal keratinocytes.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • A Genomic Analysis of Rat Proteases and Protease Inhibitors
    A genomic analysis of rat proteases and protease inhibitors Xose S. Puente and Carlos López-Otín Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain Send correspondence to: Carlos López-Otín Departamento de Bioquímica y Biología Molecular Facultad de Medicina, Universidad de Oviedo 33006 Oviedo-SPAIN Tel. 34-985-104201; Fax: 34-985-103564 E-mail: [email protected] Proteases perform fundamental roles in multiple biological processes and are associated with a growing number of pathological conditions that involve abnormal or deficient functions of these enzymes. The availability of the rat genome sequence has opened the possibility to perform a global analysis of the complete protease repertoire or degradome of this model organism. The rat degradome consists of at least 626 proteases and homologs, which are distributed into five catalytic classes: 24 aspartic, 160 cysteine, 192 metallo, 221 serine, and 29 threonine proteases. Overall, this distribution is similar to that of the mouse degradome, but significatively more complex than that corresponding to the human degradome composed of 561 proteases and homologs. This increased complexity of the rat protease complement mainly derives from the expansion of several gene families including placental cathepsins, testases, kallikreins and hematopoietic serine proteases, involved in reproductive or immunological functions. These protease families have also evolved differently in the rat and mouse genomes and may contribute to explain some functional differences between these two closely related species. Likewise, genomic analysis of rat protease inhibitors has shown some differences with the mouse protease inhibitor complement and the marked expansion of families of cysteine and serine protease inhibitors in rat and mouse with respect to human.
    [Show full text]
  • Myeloid Cell Expressed Proprotein Convertase FURIN Attenuates Inflammation
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 34 Research Paper: Immunology Myeloid cell expressed proprotein convertase FURIN attenuates inflammation Zuzet Martinez Cordova1, Anna Grönholm1, Ville Kytölä2, Valentina Taverniti3, Sanna Hämäläinen1, Saara Aittomäki1, Wilhelmiina Niininen1, Ilkka Junttila4,5, Antti Ylipää2, Matti Nykter2 and Marko Pesu1,6 1 Team Immunoregulation, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere, Tampere, Finland 2 Team Computational Biology, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere, Tampere, Finland 3 Department of Food, Environmental and Nutritional Sciences (DeFENS), Division of Food Microbiology and Bioprocessing, Università degli Studi di Milano, Milan, Italy 4 School of Medicine, University of Tampere, Tampere, Finland 5 Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland 6 Department of Dermatology, Tampere University Hospital, Tampere, Finland Correspondence to: Marko Pesu, email: [email protected] Keywords: cytokine, FURIN, LysM, macrophage, TGF-β1, Immunology and Microbiology Section, Immune response, Immunity Received: February 25, 2016 Accepted: July 22, 2016 Published: August 05, 2016 ABSTRACT The proprotein convertase enzyme FURIN processes immature pro-proteins into functional end- products. FURIN is upregulated in activated immune cells and it regulates T-cell dependent peripheral tolerance and the Th1/Th2 balance. FURIN also promotes the infectivity of pathogens by activating bacterial toxins and by processing viral proteins. Here, we evaluated the role of FURIN in LysM+ myeloid cells in vivo. Mice with a conditional deletion of FURIN in their myeloid cells (LysMCre-fur(fl/fl)) were healthy and showed unchanged proportions of neutrophils and macrophages. Instead, LysMCre-fur(fl/fl) mice had elevated serum IL-1β levels and reduced numbers of splenocytes.
    [Show full text]
  • In Glucose and Insulin Homeostasis
    MCGILL UNIVERSITY A study of the Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) in glucose and insulin homeostasis by Julie Cruanès Supervisor: Dr. Nabil G. Seidah Department of Medicine Division of Experimental Medicine McGill University Montreal, Canada December 2020 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Julie Cruanès 2020 Abstract Atherosclerotic cardiovascular disease (ASCVD) is thought to account for >30% of all deaths today. Patients at very high risk, who suffer from ASCVD and comorbidities, such as diabetes, are projected to have 10-year event risks between 26% to 43%. Considering that low- density lipoprotein cholesterol (LDLc) is the main driver of ASCVD and that reducing its circulating levels was demonstrated to be beneficial in reducing clinical events, new guidelines required patients to reduce their LDLc levels to very low levels. Therefore, therapeutic agents are currently being developed in order to decrease this societal predicament. One of the very promising agents is directed towards lowering proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis or circulating levels. Indeed, clinical trials on these PCSK9-inhibitors demonstrated safety and beneficial effects on cardiovascular outcomes. Several research groups are interested in determining whether PCSK9 may be important for other processes than cholesterol homeostasis. Indeed, some groups propose that PCSK9 could play a role in the development of diabetic dyslipidemia. Other groups are concerned over the possibility that targeting PCSK9 could lead to the excessive ectopic accumulation of cholesterol and lipid particles in insulin sensitive tissues, resulting in lipotoxicity, insulin resistance and/or impaired insulin secretion.
    [Show full text]